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STUDY QUESTION: Does loss of DMRT1 in human fetal testis alter testicular development and result in testicular dysgenesis?
SUMMARY ANSWER: DMRT1 repression in human fetal testis alters the expression of key testicular and ovarian determining genes, and
leads to focal testicular dysgenesis.
WHAT IS KNOWN ALREADY: Testicular dysgenesis syndrome (TDS) is associated with common testicular disorders in young men, but
its etiology is unknown. DMRT1 has been shown to play a role in the regulation of sex differentiation in the vertebrate gonad.
Downregulation of DMRT1 in male mice results in trans-differentiation of Sertoli cells into granulosa (FOXL2+) cells resulting in an ovarian
gonadal phenotype.
STUDY DESIGN, SIZE, DURATION: To determine the effect of DMRT1 repression on human fetal testes, we developed a novel sys-
tem for genetic manipulation, which utilizes a Lentivral delivered miRNA during short-term in vitro culture (2 weeks). A long-term (4–6 weeks)
ex vivo xenograft model was used to determine the subsequent effects of DMRT1 repression on testicular development and maintenance.
We included ﬁrst and second-trimester testis tissue (8–20 weeks gestation; n = 12) in the study.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Human fetal testes were cultured in vitro and exposed to either of two
DMRT1 miRNAs (miR536, miR641), or to scrambled control miRNA, for 24 h. This was followed by a further 14 days of culture (n = 3–4),
or xenografting (n = 5) into immunocompromised mice for 4–6 weeks. Tissues were analyzed by histology, immunohistochemistry, immuno-
ﬂuorescence and quantitative RT-PCR. Endpoints included histological evaluation of seminiferous cord integrity, mRNA expression of testicu-
lar, ovarian and germ cell genes, and assessment of cell number and protein expression for proliferation, apoptosis and pluripotency factors.
Statistical analysis was performed using a linear mixed effect model.
MAIN RESULTS AND THE ROLE OF CHANCE: DMRT1 repression (miR536/miR641) resulted in a loss of DMRT1 protein expres-
sion in a sub-population of Sertoli cells of ﬁrst trimester (8–11 weeks gestation) human fetal testis; however, this did not affect the completion
of seminiferous cord formation or morphological appearance. In second-trimester testis (12–20 weeks gestation), DMRT1 repression
(miR536/miR641) resulted in disruption of seminiferous cords with absence of DMRT1 protein expression in Sertoli (SOX9+) cells. No dif-
ferences in proliferation (Ki67+) were observed and apoptotic cells (CC3+) were rare. Expression of the Sertoli cell associated gene, SOX8,
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was signiﬁcantly reduced (miR536, 34% reduction, P = 0.031; miR641 36% reduction, P = 0.026), whilst SOX9 expression was unaffected.
Changes in expression of AMH (miR536, 100% increase, P = 0.033), CYP26B1 (miR641, 38% reduction, P = 0.05) and PTGDS (miR642, 30%
reduction, P = 0.0076) were also observed. Amongst granulosa cell associated genes, there was a signiﬁcant downregulation in R-spondin 1
expression (miR536, 76% reduction, P < 0.0001; miR641, 49% reduction, P = 0.046); however, there were no changes in expression of the
granulosa cell marker, FOXL2. Analysis of germ cell associated genes demonstrated a signiﬁcant increase in the expression of the pluripotency
gene OCT4 (miR536, 233%, P < 0.001). We used the xenograft system to investigate the longer-term effects of seminiferous cord disruption
via DMRT1 repression. As was evident in vitro for second-trimester samples, DMRT1 repression resulted in focal testicular dysgenesis similar
to that described in adults with TDS. These dysgenetic areas were devoid of germ cells, whilst expression of FOXL2 within the dysgenetic
areas, indicated trans-differentiation from a male (Sertoli cell) to female (granulosa cell) phenotype.
LIMITATIONS, REASONS FOR CAUTION: Human fetal testis tissue is a limited resource; however, we were able to demonstrate sig-
niﬁcant effects of DMRT1 repression on the expression of germ and somatic cell genes, in addition to the induction of focal testicular dysgen-
esis, using these limited samples. In vitro culture may not reﬂect all aspects of human fetal testis development and function; however, the
concurrent use of the xenograft model which represents a more physiological system supports the validity of the in vitro ﬁndings.
WIDER IMPLICATIONS OF THE FINDINGS: Our ﬁndings have important implications for understanding the role of DMRT1 in human
testis development and in the origin of testicular dysgenesis. In addition, we provide validation of a novel system that can be used to deter-
mine the effects of repression of genes that have been implicated in gonadal development and associated human reproductive disorders.
STUDY FUNDING/COMPETING INTEREST(S): This project was funded by a Wellcome Trust Intermediate Clinical Fellowship
(Grant No. 098522) awarded to RTM. LBS was supported by MRC Programme Grant MR/N002970/1. RAA was supported by MRC
Programme Grant G1100357/1. RMS was supported by MRC Programme Grant G33253. This work was undertaken in the MRC Centre for
Reproductive Health which is funded by the MRC Centre grant MR/N022556/1. The funding bodies had no input into the conduct of the
research or the production of this manuscript. The authors have declared no conﬂicts of interest.
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Introduction
Development of the mammalian testis and ovary from the bi-potential
gonad occurs through sex-speciﬁc differentiation of somatic cell popu-
lations which support the development of the gonad into a testis or an
ovary. Key to this process is the differentiation of a population of som-
atic precursor cells into either Sertoli cells (testis) or pre-granulosa
cells (ovary). In males, this process is primarily directed by the pres-
ence of a Y-chromosome, and subsequent gonadal development is
under the control of several signaling cascades working in concert to
drive cell lineage speciﬁcation in the testis (Stevant et al., 2018): In
females, speciﬁc cascades are also involved in determining ovarian
development (Pannetier et al., 2016). Once testicular somatic cell
populations are established, testosterone production from fetal Leydig
cells is initiated to induce masculinization of the fetus. Failure of normal
sex-determination or perturbed hormone production during fetal
gonadal development in humans can result in disorders of sex develop-
ment (DSD) (Jørgensen et al., 2015a; Hersmus et al., 2017) and is also
implicated in the development of testicular dysgenesis syndrome
(TDS; cryptorchidism, hypospadias, testicular cancer and low sperm
counts; Skakkebaek et al., 2016; van den Driesche et al., 2017).
Our earlier understanding of gonadal somatic cell development was
that, once speciﬁed, Sertoli and granulosa cell populations were ﬁxed.
However, it has recently been demonstrated in mice that loss of
expression of key genes in postnatal life can re-programme Sertoli cells
into granulosa cells and vice-versa, demonstrating a plasticity of
gonadal fate long after normal formation of a testis or ovary
(Uhlenhaut et al., 2009; Matson et al., 2011). DMRT1 (Doublesex and
mab-3 related transcription factor 1) is a conserved autosomal gene
expressed by both the Sertoli and germ cells in the developing mam-
malian testis (Raymond et al., 1998, 1999a). DMRT1 has been shown
to play a role in the regulation of sex determination in the vertebrate
gonad (Matson and Zarkower. 2012) and also during the mitosis to
meiosis switch in germ cells (Matson et al., 2010, Jorgensen et al.,
2012). In mice, DMRT1 expression in Sertoli cells represses ovarian
determining genes such as FOXL2 via the retinoic acid pathway
(Minkina et al., 2014). Conversely, downregulation of DMRT1 in males
during prepuberty or adulthood results in upregulation of FOXL2 and
trans-differentiation of Sertoli cells into granulosa-like cells, resulting in
an ovarian gonadal phenotype, including estrogen production (Matson
et al., 2010). Studies using DMRT1 null mice showed that despite the
lack of DMRT1 expression, mice are born phenotypically male and it is
not until after birth that they undergo sex reversal (Raymond et al.,
2000; Matson et al., 2011). These studies indicate that, in contrast to
DMRT1 homologs in other vertebrates, mammalian DMRT1 is not
involved in the initial sex determination, but is instead required for
maintaining male gonadal fate (Matson and Zarkower. 2012). In
humans, mutations and/or deletions in the short arm of Chromosome
9, where DMRT1 is located, can result in varying degrees of sex rever-
sal (Hoo et al., 1989; Bennett et al., 1993; Vinci et al., 2007) and 46,XY
individuals with DMRT1 mutations may present with DSD or features
of TDS (Murphy et al., 2015).
Much of our understanding of mammalian gonadal development is
derived from studies in mice. However, in humans, the genes and sig-
naling networks that control speciﬁcation of the fetal testis and
whether there is plasticity in somatic cell differentiation are not well
established. Research into the human relevance of ﬁndings from
rodent studies has been hampered by the lack of dynamic
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experimental model systems that can determine the effect of genetic
manipulation on subsequent development in the human fetal gonad.
In the present study, we describe a novel system for genetic manipu-
lation in the human fetal testis, which utilizes short-term in vitro culture
followed by long-term xenografting to determine the effects of gene
repression on subsequent testicular development and maintenance.
Using this system, we show that DMRT1 can be successfully repressed
in Sertoli cells of ﬁrst and second-trimester fetal testes with resulting
effects on the expression of key testicular and ovarian determining
genes, and leading to focal testicular dysgenesis in the human fetal
testis.
Materials andMethods
Experimental design
Given the evidence from rodent studies for effects of DMRT1 repression
on testicular development, we aimed to determine whether
experimentally-induced repression of DMRT1 results in aberrant develop-
ment of the human fetal testis. Effects of DMRT1 repression was studied in
human fetal testes taken from different stages of pregnancy using hanging
drop culture (ﬁrst and second-trimester testes) and a xenograft system
(second-trimester testes). Samples were exposed to scrambled miRNA
(control) or either of two miRNAs that targeted different regions of the
human DMRT1 gene. Endpoints evaluated included histological evaluation
of seminiferous cord formation and maintenance, mRNA expression levels
of testicular, ovarian and germ cell genes known to be important in gonad
development and assessment of cell number, proliferation status and of
pluripotency marker expression. Inclusion criteria and measured endpoints
were deﬁned before the start of the study. For human fetal gonad experi-
ments, the sample sizes (n = 4–8) were based on those required to
achieve statistical signiﬁcance in previous studies using the same method-
ology (van den Driesche et al., 2015). The study ended once the required
number of experiments had been conducted, and data were analyzed after
the cessation of the study. For ﬂuorescence immunohistochemistry, all
samples from the same experiment were stained in the same run. Cell
counts were determined with the investigator blind to the treatment
group. To compare the effects of treatment versus vehicle in xenografts
for each individual human fetal testis, we grafted tissue from each fetus
into replicate host mice (n = 3–6) and randomly allocated these mice to
receive tissue that had been exposed to either scrambled miRNA, miR536
or miR641.
Ethics statement and sample collection
Ethical approval for receipt and use of human fetal tissues was obtained
from the South East Scotland Research Ethics Committee (LREC08/
S1101/1) and NRES committee North East – Newcastle and North
Tyneside 1 (08/H0906/21 + 5) and written and informed consent was
provided by the pregnant women. First- and second-trimester human fetal
testes (8.5–20 weeks gestation; n = 12) were obtained after medical ter-
mination of pregnancy as described previously (Mitchell et al., 2008). None
of the terminations were due to fetal abnormalities. Gestation was deter-
mined by ultrasound scan and subsequent direct measurement of foot
length. The sex of ﬁrst trimester testes was conﬁrmed by PCR for the
male-speciﬁc gene SRY. To permit subsequent gene expression analysis,
where possible a small sample of gonad tissue was removed, snap frozen
and stored at −70°C until RNA extraction. The remainder was placed
immediately into medium containing Leibovitz L-15 with added glutamine,
10% fetal bovine serum, 1% penicillin/streptomycin and 1% non-essential
amino acids (all Sigma-Aldrich).
For studies involving animals, speciﬁc approval, including ethical
approval, was given by the UK Home Ofﬁce and all procedures were car-
ried out in accordance with the Animal (Scientiﬁc procedures) Act 1986.
Viral transduction of HEK293T cells
Recombined vectors pLent6.2_cppt_ CMV_mCherry_miR-NEG_control
containing sequences encoding scrambled miRNA (negative control), and
pLent6.2_cppt_CMV_mCherry_rDMRT1_miR536 and miR641, two
miRNA targeted against human DMRT1, were created and transfected
into HEK293T cells to produce lentiviral particles Lv-cppt-CMV-mCherry-
miR-NEG control (2.7 × 106 TU/ml), Lv-cppt-CMV-mCherry-rDMRT1-
miR536 (7 × 106 TU/ml) and miR641 (5.1 × 106 TU/ml). Brieﬂy,
DMRT1-miRNA oligonucleotides were designed using the Invitrogen
BLOCK-iT™ RNAi designer web programme to identify DNA sequences
within rat DMRT1 (transcript variant 1 accession no. NM_000044), labeled
according to their position from the translational start site. These and the
non-targeting sequence for the Scrambled miRNA are shown in
Supplementary Table S1. Targeting sequences were initially designed based
on rat DMRT1 with subsequent conﬁrmation of similarity for the human
DMRT1 sequence. Rat DMRT1 (rDMRT1) miRNA and Scrambled miRNA
oligo constructs were each cloned into a pcDNA6.2_GW_EmGFP_miR
Gateway plasmid (Invitrogen) using the BLOCK-iT™ Pol II miR RNAi
Expression Vector Kit (Invitrogen, K4935-00) according to the manufac-
turer’s protocols, and the inserts were veriﬁed by DNA sequencing before
recombining into pLent6.2 vectors. HEK293T cells were transfected with
the pLent6.2 vectors to produce the Lentivirus particles using the BLOCK-
iT™ Lentiviral Pol II miR RNAi Expression System (Invitrogen, K4937-00).
Viral transduction of tissue in a ‘hanging
drop’ culture system
Following fetal gonadal dissection, the testis was cut into small pieces
(~1 mm3). Tissue pieces were placed in ‘hanging drop’ culture in medium
spiked with the appropriate virus preparation in a total volume of 30μl/tis-
sue piece, for 24 h at 37°C under 5% CO2 (Jørgensen et al., 2015b). Tissue
was then either used for xenografting or transferred to fresh culture
medium containing alpha MEM (Lonza), 10% fetal bovine serum, 1% peni-
cillin/streptomycin, 1% non-essential amino acids, 2 mM L-glutamine,
2 mM sodium pyruvate and 1% insulin transferrin selenium (ITS) (all Sigma-
Aldrich). The latter tissue was then maintained in culture for 13 days, with
medium changed every 2 days.
Human tissue xenografting
Animals
Castrate CD1-nude (host) mice were used for xenografting studies.
Castration was performed by scrotal incision under anesthesia (inhalation
of isoﬂurane) at least two weeks prior to xenografting. For 3 days post-
castration, the mice were administered an analgesic (Carprofen, Pﬁzer) in
their drinking water.
Human tissue and xenografting procedure
As previously described (Mitchell et al., 2010), second-trimester human
fetal testes (n = 5) were grafted subcutaneously into host CD1-nude mice
using a 13-gauge cancer implant needle (Popper and sons). For each fetus,
4–6 pieces (~1 mm3) of testis tissue was inserted under the dorsal skin of
the host mouse, and grafts were distributed evenly along either side of the
midline. A total of 3–6 mice were grafted per fetus, and the mice were
maintained for 4–6 weeks post grafting before retrieval of the tissue.
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Xenograft retrieval
Host mice were killed by cervical dislocation and the retrieved xenografts
were ﬁxed in Bouin’s ﬂuid (Clin-Tech). Post ﬁxation, samples were parafﬁn
embedded, sectioned and assessed by H&E or used for immunohisto-
chemistry as below.
Immunohistochemistry
Immunohistochemistry was carried out using standard immunohistochem-
ical and immunoﬂuorescent techniques as previously described (Fisher
et al., 2003; Mitchell et al., 2008). Primary antibodies are described in
Supplementary Table SII. Images were captured either using an Olympus
Provis AX70 light microscope or in the case of ﬂuorescent images a Zeiss
LSM 510 Axio Observer Z1 confocal laser microscope (Carl Zeiss Ltd.).
All images were compiled using Zen (Blue edition, Carl Zeiss Ltd.),
Photoshop 9.0 (Adobe Systems Inc.). The total number of proliferative
(Ki67) or apoptotic (Cleaved Caspase 3) positive stained cells was quanti-
ﬁed and expressed relative to the total tissue section area for all treatment
groups (n = 4–6) in ﬁrst trimester hanging drop cultures.
Gene expression analysis
Total RNA was extracted from human fetal gonads using the RNeasy
Micro Kit with on-column DNase digestion (Qiagen, UK), as per the manu-
facturer’s instructions. Concentration and purity of the extracted RNA
was assessed using a Nanodrop 1000 spectrophotometer (Thermo Fisher
Scientiﬁc inc). cDNA was prepared using the maxima ﬁrst strand cDNA
synthesis kit (Thermo Fisher Scientiﬁc inc). Gene expression using speciﬁc
human primers (Supplementary Table SIII) was determined using SYBR
Green PCR Master Mix (Qiagen) to carry out Quantitative real time PCR
(qRT-PCR) on the ABI 7900HT (Applied Biosystems). ABI7900HT runs
consisted of a hot start at 95°C (3 min) followed by 40 cycles of 95°C
(5 sec) and 65°C (15 sec). Melt curve analysis was performed as described
previously (Bayne et al., 2004) to conﬁrm speciﬁc PCR products. Standard
curve analysis, with increasing dilutions (from 1:10 to 1:640) of control
cDNA were used to conﬁrm the efﬁciency of the PCR ampliﬁcation. All
slopes of the standard curves were close to −3.3 (equivalent to 100% PCR
efﬁciency or two-fold ampliﬁcation per cycle), allowing quantiﬁcation using
the 2−ΔΔCt method (Bayne et al., 2004). Expression levels were normal-
ized to RPS20 and RPS29 (both validated for use with human testis tissues)
and also to SOX9 (Sertoli cells) expressed as a ratio with control tissue set
to 1 (Svingen et al., 2014).
Statistics
To take into account the inter-individual variation between fetuses, the
results were analyzed using a linear mixed effects model in R (www.r-
project.org). Testicular pieces were randomly allocated to receive either
the scrambled miRNA virus or one of the DMRT1-miRNA viral constructs.
Signiﬁcance was set at P < 0.05 and no outliers were excluded.
Results
DMRT1 repression does not affect
seminiferous cord formation in the ﬁrst
trimester human fetal testis
First trimester human fetal testis tissue was exposed to lentiviral parti-
cles containing sequences that encoded either a scrambled miRNA
(control) or one of two miRNAs targeted against DMRT1 (miR536 and
miR641). Using the hanging drop culture system, testis pieces were
exposed to their respective miRNA for 24 h, followed by maintenance
in standard culture medium for a further 13 days. Initial histological
assessment of the tissue was carried out to assess survival and cellular
development, which demonstrated normal gross morphology after
culture (Fig. 1A). Cell counts for proliferating (Ki67+) and/or apop-
totic (Cleaved Caspase 3+) cells showed no signiﬁcant difference
between the control and DMRT1-targeted miRNA samples
(Supplementary Fig. S1A).
DMRT1 gene expression in the ﬁrst trimester fetal testis tissue, after
culture, was quantiﬁed using RT-qPCR (Fig. 1B,C). Due to consider-
able inter-individual variation between fetuses, no signiﬁcant difference
in DMRT1 gene expression was observed in tissues exposed to either
miR536 or miR641 when compared to scrambled miRNA-exposed
control tissue. Given that miRNA-induced changes in gene expression
are not always detectable at the transcript level, we used double
immunoﬂuorescence to determine DMRT1 protein expression. Sertoli
cells (SOX9+) devoid of DMRT1 protein expression were frequently
observed in both the miR536 and miR641-exposed tissue, indicating
effective repression, whilst in comparison DMRT1 expression was pre-
sent in all of the Sertoli cells of scrambled miRNA controls (Fig. 1D).
Seminiferous cords had not yet formed in the ﬁrst trimester con-
trols; however, cord formation could be clearly identiﬁed in all of the
tissues exposed to the scrambled control and also in those in which
partial repression of DMRT1 expression had been achieved, indicat-
ing that DMRT1 is not required for seminiferous cord formation
(Fig. 1A).
Repression of DMRT1 in second-trimester
human fetal testis alters expression of genes
involved in testicular and ovarian
development
To investigate the effects of DMRT1 repression in second-trimester
fetal testis cultures, we used the same approach as described above
for ﬁrst trimester tissues. In control tissues, seminiferous cords had
already formed and cord structure was largely maintained in the tissue
over the culture period for both scrambled and DMRT1-miRNA
(Fig. 2A). Similar to ﬁrst trimester tissue, proliferation (Ki67+ cells) was
observed in a large proportion of cells within the testis, with no dis-
cernible difference between DMRT1 repression or control tissue.
Apoptotic (Cleaved Caspase 3+) cells were rarely identiﬁed
(Supplementary Fig. S1B). These results are consistent with previously
published work using non-exposed human fetal gonadal tissue under
similar culture conditions (Jørgensen et al., 2015b).
Analysis of the mRNA expression levels of DMRT1 in the tissue at
the end of the culture period was quantiﬁed using RT-qPCR (Fig. 2B,
C). Again, no signiﬁcant difference in DMRT1 mRNA was observed for
miR536-exposed tissue compared with scrambled miRNA-exposed
controls (Fig. 2B); however, there was a signiﬁcant reduction in
DMRT1 gene expression (34%, P = 0.018) in tissue exposed to
miR641 virus compared to scrambled controls (Fig. 2C). Similar to ﬁrst
trimester tissue, there was clear inter-individual variation between
fetuses. Using ﬂuorescence immunohistochemistry, we observed a
loss of DMRT1 protein expression in Sertoli (SOX9+) cells in testes
exposed to either miR536 or miR641 (Fig. 2D).
We investigated the expression of a panel of Sertoli, granulosa and
germ cell genes shown previously to be affected by changes in DMRT1
expression in rodent studies. Second-trimester testis tissue exposed
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to miR536, miR641 or scrambled control virus and cultured as above
was assessed. For Sertoli cell associated genes, a signiﬁcant reduction
in SOX8 expression was demonstrated following exposure to either
miR536 (34%, P = 0.031) or miR641 (36%, P = 0.026), whilst expres-
sion of SOX9 was unaffected (Fig. 3A). A signiﬁcant increase in AMH
expression (100%, P = 0.033) in the miR536-exposed tissue and
Figure 1 DMRT1 knockdown does not affect seminiferous cord formation in the ﬁrst trimester human fetal testis.(A) H + E staining of pre-culture
control (left panel) and after culture for 13 days following an initial 24 h lentiviral exposure to scrambled miRNA (middle panel) or miR536 (right panel).
Seminiferous cords are delineated by broken white lines. DMRT1 mRNA expression in (B) miR536- and (C) miR641-exposed tissues compared to
scrambled miRNA controls (n = 4 for each DMRT1-miRNA exposure group). (D) Immunoﬂuorescence analysis of SOX9 (green) and DMRT1 (red)
expression in Sertoli cells in fetal testis tissue following transduction with either scrambled miRNA (left panel), miR536 (middle panel) or miR641 (right
panel) lentiviral constructs. Scale bars: (A) 20 μM and (D) 50 μM. Graphs show mean ± SEM. Data analyzed using a linear mixed effects model in R.
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downregulation of CYP26B1 (38%, P = 0.05) and PTGDS (30%, P =
0.0076) in the miR641-exposed samples was also observed.
Investigation of granulosa cell associated genes revealed a signiﬁcant
downregulation in R-spondin 1 expression in tissue transduced with
either miR536 (76% reduction, P < 0.0001) or miR641 (49% reduc-
tion, P = 0.046) DMRT1-targeted viruses. In contrast, upregulation
Figure 2 DMRT1 expression is lost in Sertoli cells of the second-trimester human fetal testis after in vitro exposure to miR536 and miR641. H + E
staining of pre-culture control (left panel) and after culture for 13 days following an initial 24 h lentiviral exposure to scrambled miRNA (middle panel)
or miR641 (right panel). Normal histological appearance of the testicular tissue is demonstrated. DMRT1 mRNA expression in (B) miRNA536- and
(C) miRNA641-exposed tissues compared to scrambled miRNA controls (n = 3 for each DMRT1-miRNA treatment group, *P < 0.05). (D)
Immunoﬂuorescence analysis of SOX9 (green) and DMRT1 (red) expression in Sertoli cells in fetal testis tissue following transduction with either
scrambled miRNA (left panels), miR536 (middle panels) or miR641 (right panels) lentiviral constructs. Scale bar (A) 20 μM and (D) 50 μM. Graphs
show mean ± SEM. Data analyzed using a linear mixed effects model in R.
6 Macdonald et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/advance-article-abstract/doi/10.1093/hum
rep/dey289/5110588 by Edinburgh U
niversity user on 02 O
ctober 2018
of ESR1 (283%, P = 0.019) was seen in response to miR536 transduc-
tion (Fig. 3B). There were no changes in expression of the granulosa
cell marker, FOXL2. Analysis of germ cell associated genes
demonstrated a signiﬁcant increase in the expression of the pluripotency
gene OCT4 (233%, P < 0.001) in the miR536-exposed tissue compared
to the scrambled control (Fig. 3C).
Figure 3 DMRT1 knockdown in second-trimester human fetal testis alters expression of genes involved in testicular and ovarian development. RT-
qPCR analysis of genes associated with development of (A) Sertoli (B) granulosa and (C) germ cells in second-trimester human fetal testes tissue cul-
ture for 13 days after an initial 24 h exposure to scrambled miRNA, miR536 or miR641. Expression was normalized to RPS29 (n = 2–3 per treatment
group, *P < 0.05, **P < 0.01, ***P < 0.001). Graphs show mean ± SEM. Data analyzed using a linear mixed effects model in R.
7DMRT1 repression causes fetal testicular dysgenesis
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/advance-article-abstract/doi/10.1093/hum
rep/dey289/5110588 by Edinburgh U
niversity user on 02 O
ctober 2018
DMRT1 repression results in ‘focal
dysgenesis’ in second-trimester human fetal
testes
We further investigated the morphology of ﬁrst and second-trimester
human fetal testis tissues in which we had identiﬁed loss of DMRT1 in
Sertoli cells (DMRT1−/SOX9+) after miRNA repression. We used
SOX9 to identify Sertoli cells, based on our earlier ﬁnding of
unchanged mRNA expression (Fig. 3). Morphology of ﬁrst trimester
tissues was similar to the corresponding (scrambled) controls
(Fig. 1A). However, in second-trimester human fetal testes, we
observed areas of disrupted seminiferous cord structure in regions
where DMRT1 expression had been lost in Sertoli cells (Fig. 4).
To determine the longer-term effects of DMRT1 repression on
these areas containing disrupted seminiferous cords, a xenograft
approach was used. Second-trimester human fetal testis tissue was
transduced as described for the in vitro experiments using miR536,
miR641 or scrambled control. After 24 h of viral exposure in culture,
the tissue pieces were transplanted into castrate CD1-nude mice
hosts and retrieved 4–6 weeks later. Viral uptake and stable transduc-
tion was conﬁrmed by immunoﬂuorescent analysis of mCherry expres-
sion in the retrieved grafts (Supplementary Fig. S2). The lack of
mCherry staining in the peripheral mouse tissue conﬁrmed viral trans-
duction was restricted to the grafted human fetal tissue and provided
an internal control for the experimental analysis.
The overall morphological appearance of the majority of the xeno-
grafted tissues was similar to that of the pre-graft control from the
same fetus, and seminiferous cord structure was largely maintained in
tissues exposed to the scrambled miRNA control, or to miR536 or
miR641 (Supplementary Fig. S3A). Cell proliferation (Ki67+) was simi-
lar between treatment groups, and apoptotic cells (Cleaved Caspase
3+; CC3) were rarely identiﬁed, indicating that all of the xenografted
tissues remained healthy (Supplementary Fig. S3B).
We performed immunohistochemical co-localization to identify
DMRT1 protein expression in Sertoli (SOX9+) cells of xenografted
human fetal testis tissues. Co-localization of DMRT1 and SOX9 was
observed in all Sertoli cells in all of the control tissues, including pre-
graft and scrambled control tissues (Fig. 5A,B), whilst DMRT1+/
SOX9− cells (presumed to be germ cells) were also evident. Exposure
to either miR536 or miR641 resulted in areas containing SOX9+/
DMRT1− cells in which there was a loss of normal seminiferous cord
structure, i.e. focal dysgenesis (Fig. 5C,D); such areas were not
observed in either untreated or scrambled control grafts from the
same fetuses. In total, sections from 4/6 of the miR536 or miR641-
exposed second-trimester fetuses exhibited areas of focal dysgenesis,
which was apparent in multiple grafts from individual fetuses
(Supplementary Fig. S4).
To analyze the focal dysgenetic areas further, we investigated cellu-
lar proliferation, apoptosis, and germ and somatic cell marker expres-
sion and compared them to control tissues (Fig. 6). Cellular
Figure 4 DMRT1 knockdown in vitro results in disruption of seminiferous cords in second-trimester human fetal testis tisse. Immunoﬂuorescence
analysis of the expression of SOX9 (Sertoli cells; green) and DMRT1 (Sertoli and germ cells; red) in fetal second-trimester testis tissue cultured for 13
days following an initial 24 h transduction with either scrambled miRNA, miR536 or miR641 lentiviral constructs. Regions of disruption of seminiferous
cords can be identiﬁed (broken white line) where DMRT1 expression has been reduced but SOX9 expression has been retained. Scale bar: 100 μM.
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proliferation (Ki67+) was similar in dysgenetic areas of miR536/
miR641-exposed testes compared either to non-dysgenetic areas or
to scrambled control tissues, whilst apoptotic (CC3+) cells were infre-
quently identiﬁed across all exposure groups (Fig. 6A and
Supplementary Fig. S3B). Leydig cell expression of the steroidogenic
enzyme CYP11A1 was seen throughout the interstitial space in
scrambled control tissue, consistent with non-exposed controls.
However, in the sections of miR536/miR641-exposed tissues contain-
ing focal dysgenetic areas, CYP11A1 expression appeared to be
reduced in regions surrounding the seminiferous cords with a ‘normal’
appearance and was minimal or absent in the regions surrounding focal
dysgenetic areas. Furthermore, within the dysgenetic regions (devoid
of DMRT1+ Sertoli cells), CYP11A1 expression was completely absent
(Fig. 6B).
We investigated the expression of germ cell markers, AP2γ (gono-
cyte) and MAGE-A4 (pre-spermatogonia) in both scrambled controls
and testis tissue with focal DMRT1 repression. In scrambled control
tissues, we identiﬁed frequent AP2γ+ and MAGE-A4+ germ cells
within the seminiferous cords, similar to previous studies in second-
trimester human fetal testis tissues (Mitchell et al., 2008). However, in
the dysgenetic areas of the miR536/miR641-exposed xenografts,
AP2γ+ cells were rarely observed (Fig. 6C). MAGE-A4+ cells were
identiﬁed in seminiferous tubules on the periphery of the dysgenetic
regions, but were rarely identiﬁed within the focal dysgenetic areas
(Fig. 6C).
Previous studies in rodents have demonstrated that downregulation
of DMRT1 expression in the male gonad can result in male to female
sex reversal with trans-differentiation of the Sertoli cells (SOX9+) to
granulosa-like cells (FOXL2+) cells (Matson et al., 2011). To investi-
gate the possibility of somatic cell trans-differentiation in the long-term
xenografted tissue, we performed immunoﬂuorescent analysis for
FOXL2 expression in control and dysgenetic tissue samples. FOXL2
expression was not observed in any of the scrambled control tissues;
however, we identiﬁed FOXL2 expression in tissue from one of ﬁve
fetuses from miR536 transduced testes, and this was within a dysge-
netic region devoid of DMRT1 expressing cells (Fig. 7).
Discussion
Impairment of normal development of the human gonad during fetal
life may have implications for future reproductive potential and the
development of gonadal tumors (Looijenga et al., 2010; Jørgensen
et al., 2015a; Hersmus et al., 2017); this has been the foundation for
the TDS hypothesis (Skakkebaek et al., 2016). An increasing number
of genetic mutations associated with DSD are being described in
humans; however, much of our understanding of these mutations and
Figure 5 DMRT1 knockdown results in ‘focal testicular dysgenesis’ in second-trimester human fetal testis xenografts. Double immunohistochemistry
for DMRT1 (brown; Sertoli and germ cells) and SOX9 (blue; Sertoli cells) in (A) pre-graft control, or after xenografting for 6 weeks following an initial
24 h transduction period in culture with (B) scrambled miRNA, (C) miR536 or (D) miR641. Red asterisk = normal seminiferous cord structure, black
arrowheads show areas of cord breakdown and the absence of DMRT1 protein; black arrows indicate germ cells and DYS identiﬁes focal dysgenetic
areas in which there has been a complete breakdown of seminiferous cords. Scale bar: 50 μM.
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the mechanism(s) by which they result in testicular dysfunction is
based on rodent studies. Mutations/deletions in the short arm of
Chromosome 9, where DMRT1 is located is strongly associated with
DSD and sex-reversal in humans (Raymond et al., 1999b; Ottolenghi
et al., 2000; Ounap et al., 2004; Vinci et al., 2007) and a recent study
has reported a patient with XY sex-reversal associated with a point
mutation in DMRT1 (Murphy et al., 2015). Recent evidence from
rodent studies show that inducing DMRT1 mutations, even in postnatal
life, can lead to trans-differentiation of the gonad from a testicular to
an ovarian phenotype, demonstrating plasticity in gonadal fate through-
out life (Matson et al., 2011). In this study, we developed a novel sys-
tem of lentiviral mediated miRNA manipulation to target a gene of
interest in the human fetal testis, which combined in vitro culture with a
xenografting approach to investigate the short- and long-term conse-
quences of manipulation. This approach was used to determine the
effects of reduced DMRT1 expression on testicular development and
assess whether plasticity of gonadal fate exists in humans as in rodents.
We show that DMRT1 expression can be repressed in Sertoli cells of
the human fetal testis resulting in altered expression of gonad-speciﬁc
genes and proteins, indicating a move away from a fully differentiated
male phenotype, and potentially towards a more ovarian-like pheno-
type. Moreover, we demonstrate that DMRT1 repression in the
human fetal testis results in disruption of prior-formed seminiferous
cords with development of focal testicular dysgenesis. A similar
Figure 6 Germ and somatic cell composition and function is altered in ‘focal dysgenetic’ regions of second-trimester human fetal testis resulting
from DMRT1 knockdown. Double immunoﬂuorescence for (A) Ki67 (green; proliferation marker) and Cleaved Caspase 3 (red; apoptotic marker),
(B) DMRT1 (green; Sertoli and germ cells) and CYP11A1 (red; Leydig cells), and (C) AP2γ (green; gonocytes) and MAGE-A4 (red; pre-spermato-
gonia). Nuclear counterstain (gray; DAPI/Hoescht). Focal dysgenetic areas are indicated by dashed white lines. White asterisk highlights a single
AP2γ+ germ cell within a dysgenetic area (bottom right panel), White arrow indicates a surviving MAGE-A4+ germ cell within a dysgenetic area.
Scale bar: 50 μM.
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disruption of prior-formed seminiferous cords has been reported also
in rats after exposure to an environmental chemical (dibutyl phthal-
ate), and shown to result in focal dysgenesis (Lara et al., 2017).
We have validated a dynamic model system for genetic manipulation
of the human fetal testis by transducing ﬁrst and second-trimester tes-
tis tissue with miRNAs targeting the DMRT1 gene at two separate
regions (miR536 and miR641). This resulted in repression of DMRT1
expression in focal regions of exposed human fetal testis tissue pieces
after 14 days of culture. DMRT1 repression was observed at the pro-
tein level in both ﬁrst and second-trimester human fetal testes with
either DMRT1-targeted miRNA, although the DMRT1 mRNA tran-
script level was only reduced in second-trimester tissue transduced
with the miR641 transcript. The lack of identiﬁable transcript alteration
in both ﬁrst and second-trimester tissues with each of the miRNAs is
not unusual given that miRNA can result in either translational repres-
sion or endonucleolytic activity resulting in mRNA degradation and is
dependent on the level of complementarity with the target mRNA
(Schmitter et al., 2006). The targeting region of the RT-qPCR primers
used to detect repression in relation to the miRNA target site can also
inﬂuence the ability to identify gene repression at the mRNA level
(Holmes et al., 2010). Although we have previously shown that it is
possible to inhibit and promote signaling pathways in fetal testis gonad
culture using chemical manipulation (Jørgensen et al., 2015b), to the
best of our knowledge there are no publications showing successful
‘long-term’ genetic manipulation of the human fetal gonad. We have
shown that repression of DMRT1 activity persists over several weeks
in this study by using xenografting techniques to extend the experi-
mental time from 14 days (in culture) to 4–6 weeks (via xenografts),
after which time SOX9+/DMRT1− cells were still frequently identiﬁed
in testis tissue exposed to DMRT1-targeted miRNA. The location of
the DMRT1 repression appears to relate to the degree of viral pene-
tration within the tissue and the resulting focal areas of dysgenesis are
likely to result from proliferation of the DMRT1− Sertoli (SOX9+)
cells. The focal distribution of DMRT1 repression and corresponding
dysgenesis also provides a useful internal control for identifying speciﬁc
effects of gene repression within each tissue sample.
Figure 7 DMRT1 knockdown results in FOXL2 expression in a region of ‘focal dysgenesis’ in a second-trimester human fetal testis xenograft.
FOXL2 protein expression in xenografts of control and DMRT1-miRNA transduced second-trimester human fetal testis tissue. (A) Double immuno-
histochemistry for SOX9 (Blue) and DMRT1 (brown) identiﬁes regions of loss of DMRT1 with ‘Focal Dysgenesis’. (B) FOXL2 immunoexpression
(green) in scattered cells in one fetus in an area devoid of DMRT1 (red) expression following initial transduction with miR536. Scale bar: 20 μM.
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It has previously been shown that DMRT1 is important for maintain-
ing the testicular phenotype by preventing Sertoli-to-granulosa cell
trans-differentiation in the postnatal mouse testis by inhibiting the
expression of key ‘female pathway’ genes whilst promoting the contin-
ued expression of ‘male pathway’ promoting genes (Matson et al.,
2011; Minkina et al., 2014). To examine potential effects of DMRT1
repression in Sertoli cells on genes known to be linked to maintenance
of gonad sex identity, we used RT-qPCR to investigate expression of
Sertoli, granulosa and germ cell speciﬁc genes. Notably, SOX8 expres-
sion was reduced in both the miR536 and miR641-exposed tissues.
This is in agreement with a rodent study which elegantly demonstrated
that when DMRT1 was knocked out in both prepubertal and adult
male mice, it resulted in down- regulation of SOX8 and SOX9 (Matson
et al., 2011). Unlike Matson et al. (2011) we did not observe a reduc-
tion in SOX9 expression following DMRT1 knockdown in postnatal
mice, although this is in keeping with studies involving Dmrt1 deletion
in mice, in which Sox9 expression is initially independent of DMRT1
(Matson et al., 2011). It is possible that loss of Sox9 after Dmrt1 abla-
tion is a secondary consequence of the upregulation of ovarian genes
(s), such as Foxl2, which does not occur until postnatal life (Matson
et al., 2011). Whilst SOX9 is essential for sex determination, it has
been shown in some studies to be dispensable for the maintenance of
sexual phenotype beyond fetal life (Chaboissier et al., 2004), although
this conclusion does not take into consideration the importance of
continued expression of DMRT1 or SOX8 (Barrionuevo et al., 2016).
It is possible that DMRT1 and SOX9 provide a protection system for
the maintenance of sexual phenotype in the male gonad during differ-
ent stages of development. In contrast, SOX8, remains a potential can-
didate as a key sexual maintenance gene in the male gonad
(Barrionuevo et al., 2009, 2016). Furthermore, mutations in SOX8
have recently been demonstrated in humans with DSD and a lack of
testis determination (Portnoi et al., 2018).
Other than SOX8, no other ‘male pathway’ genes were found to be
differentially altered after knockdown of DMRT1, although CYP26B1
and PTGDS (Prostaglandin D2 synthase) were both down-regulated in
the miR641 transduced samples. CYP26B1 and DMRT1 are both
involved in preventing premature initiation of meiosis in rodent fetal
testes by repression of retinoic acid (RA) signaling, including inhibiting
the expression of the pre-meiosis marker STRA8 (Bowles et al., 2006;
Koubova et al., 2006; Matson et al., 2010). In addition, the CYP26B1
expression which is activated by SOX9 in the fetal mouse testis was
recently shown to also antagonize the ovarian differentiation pathway
possibly through the involvement of DAX1 (Bowles et al., 2018). In
terms of genes associated with an ovarian phenotype, the granulosa
cell marker R-spondin 1 was down-regulated despite repression of
DMRT1, whilst there was no change in FOXL2 expression at a tran-
script level. However, we did identify FOXL2 protein expression in tis-
sue from one of the xenografted fetuses in an area of the tissue in
which DMRT1 was repressed, whilst no expression of FOXL2 was
detected in the control xenografts from the same fetus. This might
indicate that a longer time-period of DMRT1 repression is required for
FOXL2 expression to be initiated, as analysis of xenografts occurred
4–6 weeks later than for the cultured tissues. The rare ﬁnding of
FOXL2 expression in the xenografted tissue could indicate that there
are several pathways or factors working in concert to maintain a
gonadal phenotype, a concept that is supported by descriptions of sig-
niﬁcant inter-individual variation in the occurrence of male to female
sex reversal in patients with various forms of XY gonadal dysgenesis
(Bagheri-Fam et al., 2015). In addition, the potential for DMRT1
repression to induce FOXL2 expression may be reduced in the xeno-
grafts due to the fact that DMRT1 is only lost in a proportion of the
Sertoli cells or that focal expression of these FOXL2+ cells may be
restricted by a low rate of their proliferation.
A key ﬁnding of the study was the demonstration of regions of focal
dysgenesis in the second-trimester human fetal testis as a result of
DMRT1 repression. Whilst seminiferous cord formation progressed in
ﬁrst trimester human fetal testes in which DMRT1 was repressed,
DMRT1 repression in second-trimester tissue, in which the seminifer-
ous cords had already formed, resulted in localized disruption of cord
structure after short-term in vitro culture. Long-term maintenance of
the testis tissue in xenografts showed further progression of cord
breakdown into regions of focal dysgenesis. These ﬁndings indicate a
role for DMRT1 in the maintenance of testicular phenotype following
sex determination and seminiferous cord formation in the human tes-
tis. This is in keeping with data from rodent studies where Dmrt1 null
XY mice initially develop testes but subsequently undergo male to
female sex reversal (Raymond et al., 2000). Whilst the present study
suggests that DMRT1 is required to maintain the testicular phenotype
during fetal life in humans, studies in Dmrt1ﬂ/ﬂ mutant mice show that
trans-differentiation towards a female phenotype does not begin until
around postnatal Day 8 (Minkina et al., 2014). Furthermore, the latter
authors demonstrated that trans-differentiation was more pronounced
in the Dmrt1−/Sox9- double knockout, evidenced by increased num-
bers of FOXL2+ cells by 14 days and almost complete sex reversal at
5 weeks compared to the Dmrt1- only mutant. In the present study
SOX9 expression was unaffected and therefore it is unclear whether
simultaneous loss of SOX9 would lead to a more frequent or severe
gonadal phenotype. Taken together, these results suggest that, similar
to the mouse, DMRT1 is not essential for seminiferous cord formation
in the human fetal testis, but is required for subsequent maintenance
of the seminiferous cords and for the prevention of trans-
differentiation to an ovarian phenotype. In the context of testicular
dysgenesis syndrome (TDS) disorders, the present results suggest that
the focal dysgenesis which is frequently observed in the testes of
patients with reproductive disorders (Skakkebaek et al., 2016), could
arise as the result of the breakdown of already formed seminiferous
cords, as recently documented in an animal model of TDS (Lara et al.,
2017; van den Driesche et al., 2017). Moreover, the fact that DMRT1-
miRNA-induced focal dysgenesis was associated with evidence for
impaired Leydig cell steroidogenesis, as indicated by reduced
CYP11a1 expression, ﬁts with the clinical (Skakkebaek et al., 2016)
and rodent experimental (van den Driesche et al., 2017) data, and this
is considered to be the underlying cause of some of the TDS
disorders.
The present ﬁndings have important implications for the study of
DSD and TDS. Focal testicular dysgenesis is frequently found in
patients with these disorders and there is a strong association between
DSD (Y-chromosome+) and testicular germ cell tumors (TGCC;
Looijenga et al., 2010; Jørgensen et al., 2015a; Hersmus et al., 2017).
Indeed, in humans, the presence of focal dysgenesis has been shown
to correlate with the presence of germ cell neoplasia in situ (GCNIS),
the precursor to TGCC (Hoei-Hansen et al., 2003; van den Driesche
et al., 2017) and genetic variations in or near to DMRT1 have also
been associated with TGCC in GWAS studies (Turnbull et al., 2010;
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Kanetsky et al., 2011). Indeed, DMRT1 is aberrantly expressed in the
testicular cancer precursor germ cell neoplasia in situ (GCNIS) as part
of a general dysregulation of the mitosis-meiosis switch in these cells
(Jorgensen et al., 2013; Sharpe and Mitchell, 2013). Further support
for a potential role of DMRT1 in the pathogenesis of TGCC is the pre-
sent ﬁnding that PTGDS gene expression was also down-regulated fol-
lowing DMRT1 repression (miR641) in the human fetal testis. PTGDS
expression has been associated with inhibition of cellular proliferation
and migration in the human testicular germ cell cancer line NT2 (Wu
et al., 2012a; Shyu et al., 2013). GCNIS cells (and gonocytes) express
markers including the pluripotency factors OCT4 and AP2γ: we have
shown a signiﬁcant increase in OCT4 gene expression following
DMRT1-miRNA (miR536) repression. Furthermore, in xenografts,
repression of DMRT1 resulted in focal dysgenesis similar to that
described in patients with TGCC (Hoei-Hansen et al., 2003).
However, germ cells expressing AP2γ were rarely observed in the dys-
genetic regions of xenografted human fetal testes in which DMRT1
had been repressed. Whether the few remaining germ cells within
these dysgenetic regions undergo pre-neoplastic change requires fur-
ther investigation.
More widely, the use of this novel system for genetic manipulation in
human fetal testis provides a unique opportunity to determine the role
of other genes or gene networks that may be involved in testicular
development in health and disease (including DSD and TDS). This may
include studies to determine the human-relevance of results from
rodent models or those that can investigate the pathogenicity and
potential mechanism(s) for mutations identiﬁed in patients with these
disorders.
In conclusion, the present study has utilized a novel approach for
genetic manipulation in the human fetal testis, resulting in the ﬁrst dir-
ect evidence that DMRT1 is required for testicular differentiation in
humans. We have shown that DMRT1 repression results in alterations
in expression of key genes involved in gonadal development, consist-
ent with DMRT1 preventing trans-differentiation of Sertoli cells to a
more granulosa-like cell type in the human testis. Furthermore, we
have demonstrated that repression of DMRT1 results in focal dysgen-
esis in the human fetal testis. These ﬁndings relating to DMRT1 effects,
coupled with the potential use of this system to investigate the effects
of manipulation of other genes, may have important implications for
understanding the origins of DSD, TGCC and related disorders in
humans.
Supplementary data
Supplementary data are available at Human Reproduction online.
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